When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AIMT - Aimmune's Palforzia shows durable effect in follow-on peanut allergy study
Aimmune Therapeutics Inc.
New data from an open-label follow-on study, ARC004, from the 52-week PALISADE trial showed a durable treatment effect of Aimmune Therapeutics' (NASDAQ:AIMT) Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first peanut allergy treatment approved (late January) in the U.S. The results are being presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting in Philadelphia.
More news on: Aimmune Therapeutics, Inc., Healthcare stocks news,